Underlying profit +5.7% but operating cash fell 23% as borrowings jumped 46%

What changed

Revenue rose 12.4% to NZ$128.2m and management's underlying profit measure increased 5.7% to NZ$87.2m. On an IFRS basis, however, operating profit was essentially flat at NZ$140.7m, profit before tax fell 5.0% to NZ$128.1m, and NPAT slipped only 1.2% to NZ$133.1m because a NZ$5.0m tax credit replaced a small prior expense. Unit sales of occupation rights fell to 483 from 511. On the balance sheet, total assets grew 17.2% to NZ$6.30b and equity rose 11.8% to NZ$2.31b, but gross borrowings climbed 46.0% to NZ$1.29b, taking net debt from NZ$849.5m to roughly NZ$1.26b. Operating cash flow dropped 23.0% to NZ$146.7m and the interim dividend was lifted 5.6% to 11.3 cents.

What matters

• Leverage is the main read-through. Borrowings expanded by NZ$407.7m in twelve months while cash barely moved, funding the asset build that lifted total assets by NZ$922.8m. This is a deliberate balance-sheet expansion, but the direction is unambiguously more leveraged.
• PBT is the cleaner operating read, and it is down. NPAT benefited from a NZ$4.95m tax credit versus a NZ$0.3m expense in HY22; stripping the tax distortion, pre-tax earnings fell 5.0% even as revenue grew 12.4%, implying operating margin compression despite the reported 33.5% development margin (up from FY22's 29.7%).
• Underlying vs. reported gap widened. Underlying profit of NZ$87.2m grew 5.7% while IFRS PBT fell 5.0%. Without a full bridge in the extracted material, the two measures are giving different signals on the operating run-rate.

Expectations

No formal guidance or forward-work metrics were disclosed in the extracted data. On seasonality, HY22 represented 47.8% of FY22 revenue and 50.0% of NPAT, so the pattern has historically been modestly second-half weighted on the top line. Annualising HY23 revenue gives NZ$256.5m, about 7.5% above FY22's NZ$238.7m, which is consistent with growth but leaves the FY23 outcome dependent on settlement timing in the second half. The release does not support a specific volume or earnings target beyond the 483 half-year settlements already booked.

Quality of result

The result is mixed on durability. The headline NPAT is flattered by the tax swing; PBT of NZ$128.1m is the more defensible number and it is down year-on-year. Cash conversion deteriorated materially: operating cash flow fell NZ$43.8m while capex rose to NZ$29.4m from NZ$23.6m, so pre-lease free cash flow declined to NZ$117.2m from NZ$166.9m, and FCF/NPAT coverage dropped from 123.9% to 88.1%. Trade receivables fell from NZ$63.2m to NZ$40.5m (receivable days 100.7 to 57.6), which helped rather than hurt cash, so the OCF weakness is not a debtors story — it points to other working capital or settlement timing effects not itemised in the excerpts. ROE slipped to 5.8% from 6.5%, consistent with a larger asset base earning similar absolute profit.

Unresolved

• What drove the NZ$43.8m decline in operating cash flow given that trade receivables were a source, not a use, of cash?
• What is the full reconciliation between IFRS PBT (down 5.0%) and underlying profit (up 5.7%), and which fair-value or deferred-tax items moved?
• How should the 46.0% jump in gross borrowings be read against the development pipeline, and what covenant headroom or net-debt/EBITDA ceiling applies?
• Why did occupation-right sales fall to 483 from 511 despite a 33.5% development margin, and is this a demand or a delivery-timing signal?

This briefing cannot assess Summerset's embedded value, resale pipeline, or covenant position, because NTA, deferred management fee roll, and debt facility terms were not present in the extracted material.

Key metrics

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.